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Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and sometimes the only curative
therapy for patients with certain hematological diseases. Allo-HSCT has been practiced in China for approximately
30 years, and great improvements have been made within the past decade, particularly in fields such as the
haploidentical HSCT system, strategies to overcome relapse and GVHD, and modified HSCT for elderly patients. This
review will describe the current situation and provide a prospective of these unique aspects of Allo-HSCT in China.
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Current status of Allo-HSCT in China
I th a sb e e nm o r et h a nt h i r t yy e a r ss i n c et h ef i r s ta l l o -
geneic bone marrow transplantation was successfully
performed in China [1], and during the past decades,
substantial progress has been made in the field of allo-
geneic hematopoietic stem cell transplantation (allo-
HSCT).
Currently, there are 104 transplant units certified by
China’s Ministry of Health and the China Marrow Donor
Program. Of these centers, 60% are active and routinely
perform HSCT. According to data collected from 50 active
centers by the Chinese Hematopoietic Stem Cell Trans-
plantation Registry Group (2007-2011), 5 centers per-
formed more than 100 HSCT cases annually, and
approximately 30 centers performed 20-100 cases per
year. The total number of HSCT cases in all 50 active cen-
ters increased steadily from 1093 cases in 2007 to 1633
cases in 2010 [2]. By the end of 2011, this figure has been
greater than 2000 by the preliminary statistics.
The types of donor sources for Allo-HSCT in China are
related identical (47.3%), related mismatched/haploidenti-
cal (30.8%), unrelated matched (12.1%), unrelated mis-
matched (7.7%), umbilical cord blood (UCB, 2.2%) and
Allo-HSCT accounts for 91% of the total HSCT cases.
(Figure 1) [2]. These data are quite different from those
reported by the CIBMTR(Center for International Blood
and Marrow Transplant Research), which show that auto-
logous HSCT takes up 58% of the total HSCT cases and
that unrelated donors comprise nearly half of all the allo-
geneic HSCT graft sources in the USA. Data on haploi-
dentical HSCT(Haplo-HSCT) cases are not available [3].
The distribution of diseases occurring in allogeneic trans-
plant recipients is as follows: acute myeloid leukemia
(AML) (34%), acute lymphoblastic leukemia (ALL) (24%),
chronic myeloid leukemia (CML) (20%), myelodysplastic
syndrome (MDS) (7%), aplastic anemia (AA) (7%), Medi-
terranean anemia (MIA) (2%), non-Hodgkin’s lymphoma
(NHL) (3%), and other diseases (2%) (Figure 2). The pro-
portions of disease types receiving allo-HSCT are similar
to those reported by the CIBMTR. However, although the
overall number of allo-HSCT cases in CML patients has
decreased gradually in recent years, these patients still
make up a relatively large proportion of the total allo-
HSCT cases (approximately 20%). This is due to the
potential accumulated expenses of tyrosine kinase inhibi-
tors for young CML patients as well as the significant sur-
vival advantage of allo-HSCT compared with imatinimb
treatment for patients with AP CML [4].
The unique characters of Chinese HSCT system
Though research resources for HSCT in China are lim-
ited, for example, HSCT researchers are allotted only
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National Science Foundation in hematology, an increas-
ing number of clinical and applied fundamental research
studies in HSCT have been published in influential jour-
nals or presented orally at the American Society of
Hematology (ASH) annual meeting. Also, HSCT in
China is not just imitation, there are some characteristic
aspects which may contribute to other HSCT programs
around the world.
These unique characters of Chinese HSCT system can be
divided into four categories: ① Haplo-HSCT system, ②
strategies to overcome relapse and ③ GVHD, and ④ mod-
ified HSCT for elderly patients. The initiation of multi-cen-
ter clinical trials and advances in translational research are
important for promoting progress in HSCT methods in
China.
Evidence-based and mechanism research on Haplo-HSCT
Haplo-HSCT is one of the acceptable alternatives in the
absence of HLA-matched siblings or unrelated donors
[5,6]. There are three main strategies to complete Haplo-
HSCT: T cell-depleted myeloablative HSCT, unmanipu-
lated myeloablative HSCT, or nonmyeloablative/reduced
intensity conditioned HSCT [5,7]. Transplantation with
T cell-depleted peripheral blood progenitor cells has a low
rate of GVHD, but these transplants are associated with
slow immune recovery, a high rate of relapse, and a sub-
stantial risk of treatment-related mortality [8]. Nonmye-
loablative Haplo-HSCT shows relatively lower nonrelapse
mortality but a higher rate of overall relapse [9]. The typi-
cal Haplo-HSCT systems around the world are summar-
ized in (Table 1) [8-16].
Due to the “One Child Policy”, there has been a shortage
of HLA-identical siblings for Chinese patients who need
HSCT; what’s more, the donor pool of Chinese Marrow
Donor Program and cord blood banks are still relatively
small in view of the massive Chinese population [17],
Therefore haplo-HSCT based on related family donors has
a unique role in the treatment of hematologic disease in
China. Peking University researchers developed a novel
approach for HLA-mismatched/haploidentical myeloabla-
tive blood and marrow transplantation without in vitro T
cell depletion within the past 10 years (the GIAC protocol).
This protocol includes the following steps: treating donors
with granulocyte colony-stimulating factor (G-CSF) to
induce donor immune tolerance, intensified immunological
suppression to both promote engraftment and prevent
GVHD, antithymocyte globulin (ATG) administration for
the prophylaxis of GVHD and graft rejection, and combi-
nation of G-CSF-primed bone marrow harvest (G-BM)
and G-CSF-mobilized peripheral blood stem cell harvest
(G-PB) as the source of stem cell grafts [18-21]. A single-
center study reported that unmanipulated myeloablative
HSCT using the GIAC protocol has similar LFS/grade, III-
IVaGVHD/extensive, chronic GVHD compared with
HLA-matched sibling transplantation or matched unre-
lated donor transplantation [19,21]. The GIAC protocol
also demonstrated improved GVL effects [22]. Also, modi-
fied haploidentical nonmyeloablative transplantation with-
out T cell depletion and haploidentical PBSCT have been
successfully launched as routine procedures in other cen-
ters in China [16,23]. Besides Hematological malignancies,
haplo-HSCT has become a feasible and safe treatment for
nonmalignant hematological diseases, such as severe aplas-
tic anemia [24]. Based on the extensive application,
together with unique immunomodulatory strategies for
relapse (Referred to 2.2) and mechanism researches, haplo-
HSCT of China has developed to a characteristic system.
To date, haplo-HSCT accounts for approximately 30% of
the total allo-HSCT cases per year in China, and in some
experienced centers, such as Peking University Institute of
Hematology, this proportion has consistently exceeded
60%, and the cumulative haploidentical cases increased to
more than 1300 in single center at the end of 2011.
Figure 1 The types of donor sources for allo-HSCT in China.
Figure 2 The distribution of diseases of allo-HSCT recipients in
China.
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Patients
(n)
Disease Conditioning Graft/ Manipulation GVHD Prophylaxis GF aGVHD cGVHD TRM LFS/DFS Nation Reference
104 AL ST:TBI/thiotepa/
fludarabine/ATG
PB/CD34+ selection No 1st
6.9%
(II-IV)
7.9%
7.1% 36.5% AL CR:46%-48% Italy Aversa
(2005)[8]
49 AL/MDS/ CML/
MPD
RIC: Flu+Cy/ anti-CD52 PB/anti-CD52 CsA+MMF 6% (II-IV)16% 14% 10.2% 31-63%@1-3 year U.S.A Rizzieri
(2007)[10]
24 AL/AA ST:TBI/CY BM/costimulatory
blockade
CsA+MTX 5% (III-IV)
23.8%
8.3% 50% 33%@7 years U.S.A Guinan
(2008)[11]
60 AL/NHL/ CML/
MM
RIC:Flu/Mel/OKT-3/
thiotepa
PB/CD3+CD19
depletion
No if CD3+T < 5 ×
104/kg
0 (II-IV)47% 15% 25%@100
days
44%@7
years
HR 41%@1 year 24%@2
years
Germany Federmann
(2009)[12]
66 AL/MDS RIC:TBI/flu/Bu/ATG/
melphalan
PB or BM/No FK506 6.1% (II-IV)38% 33.3% 59.1% 28.8%@4 years Japan Kurokawa
(2010)[13]
820 AL/CML/ NHL/
AA
ST:Bu/Cy/Ara-C/MeCCNU/
ATG
BM+PB/No CsA+MTX +MMF < 1% (II-IV)
42.9%
(III-IV)
14.0%
Total
53.7%
Ex 23.4%
@2 years
21%@2
years
SR68.1% HR47.1%
@2 years
China Huang
(2011)[14]
83 AL/MDS RIC:Bu/Flu/ATG PB/No CsA+MTX 0 24% 28% 17%@1 year AML/MDS
CR53%-60%;
AML RE9%
Korea Lee
(2011)[15]
50 AL/MDS RIC:Cy/Flu/TBI BM/No Cy(HD)+ FK506+MMF 4% (II-IV)32% 13% 7%@1 year 46%@1 year U.S.A Fuchs
(2011)[9]
21 AL/CML ST:Bu/Cy/ MeCCNU/ATG PB/No CsA+MTX +MMF 0 (II-IV)
33.8%
39.5% 20%@2
years
55.6%@2 years China Yu
(2012)[16]
HLA Human leukocyte antigen; AL Acute Leukemia; CML chronic myelogenous leukemia; MDS myelodysplastic syndrome; ST Standard intensity/Myeloablative; RIC reduced intensity; Bu Busulfan; Cy
cyclophosphamide; Ara-C aracytidine; TBI total-body irradiation; MeCCNU Semustine; CsA cyclosporine A; MMF Mycophenolate mofetil; Flu fludrabine; ATG antithymocyte globulin; FK506 Tacrolimus; anti-CD52
alemtuzumab; GF graft failure; HR high risk; SR standard risk; Re refractory; Ex extensive; GVHD Graft versus host disease
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8Though the HLA polymorphism of China is more het-
erogeneous than that of Japan and Korea, as there are 56
different nationalities in China and the main nationality
“Han” also varies in HLA alleles across the vast mainland
[25-28]; Haplo-HSCT become more popular in China
because of both the well-established clinical regimen and
the shortage of sibling and unrelated donors, whereas
Japan and Korea marrow donor program have satisfied
the need for donors in their countries [26]. What’sm o r e ,
the HLA polymorphism of continental Northeast Asia
varies similar to that of Europe and North America [29],
which suggest experience of haplo-HSCT in China may
be exportable in Europe and North America.
Nevertheless, there are still several problems confronting
the future development of haplo-HSCT. First, although
the underlying mechanism of crossing the HLA barrier
has been partially explained by a series of in vitro and
in vivo studies: ①G-CSF leads to T cell hyporesponsive-
ness and modulates the balance between Th1 and Th2
immune responses [30]; ②G-CSF treatment significantly
decreased the expression of VLA-4, ICAM-1, L-selectin,
and LFA-1 on naïve CD4
+ and CD8 + T cells in bone
marrow grafts. It was also found easier to polarize T cells
from Th1 to Th2 in G-BM compared with G-PB [31]; ③T
cell hyporesponsiveness and polarization of T cell from
Th1 to Th2 could be maintained after in vitro mixture of
G-PB and G-BM, besides the benefits of independent
component [32]. ④Depletion of infused donor lympho-
cytes in vivo by ATG, and induction of regulatory T cells
[33], etc. However, the complete story has not yet been
elucidated. For example, in contrast with ex vivo T cells
depletion haplo-HSCT model [34], our finding showed
that KIR ligand mismatch is associated with higher
aGVHD, a greater relapse rate and inferior survival in our
unmanipulated HSCT system [35]; additional results sug-
gested that NK cell allo-reactivity could be covered by
massive T cells [36], which need further investigation. Sec-
ond, reports from single centers are not as convincing as
those from multi-center clinical trials. Evaluating a uni-
form haplo-HSCT protocol, such as GIAC, in more Chi-
nese clinical centers would enable prospective, multi-
center trials on the standardized treatment. These types of
studies would hopefully aid in evaluating the roles of
haplo-HSCT in some uncertain situations.
Mechanism and management of relapse after HSCT
Relapsing hematologic malignancy after HSCT remains a
major cause of death for patients, and finding methods to
trigger a more potent graft-versus-tumor effect without
increasing the risk of GVHD is still the ultimate goal of
HSCT. Many Chinese researchers have attempted to
address this challenge.
In a recent study, Huang and his colleagues provide
the first report of multiple mutations of CEBPA that
contribute to the transformation of donor cells to the
leukemic phenotype and provide clues of relapse from
donor origin. Huang found that after the first genetic
mutation involved in leukemogenesis occurs in the
donor, the susceptible donor cells can acquire second or
third mutations in different genes or recessive mutations
in a single gene after transplantation to the recipient’s
particular microenvironment. This acquisition of muta-
tions can lead to overt leukemic transformation and
cause relapse. This mechanism provides a unique view-
point that aids our understanding of the process of
relapse due to the “multiple genetic-hits mechanism”
and suggests that the targeting of mutated genes may be
ap o s s i b l es t r a t e g yt op r e v e n tr e l a p s e[ 3 7 ] .M e a n w h i l e ,
D i a m o n de ta l .f o u n dr e l a p s eo fA M La f t e ra l l o - H S C T
from donor origin who harbors germline XPD and
XRCC3 polymorphisms resulting in low DNA repair
capacity [38]. These research together emphasize the
importance of gene polymorphisms in selecting candi-
date donors prior to allo-HSCT.
There is a large gap between laboratory research and
clinical application; however, by integrating minimal resi-
dual disease (MRD) monitoring and modified donor lym-
phocyte infusion (mDLI), researchers at Peking University
have improved the management of relapse following
HSCT in the clinic [39]. Traditional DLI with steady-state
lymphocytes has been shown to effectively treat relapse,
but it often causes severe GVHD [40]. However, data from
other study showed that replacing steady-state lympho-
cytes with G-PB and applying a short course of immuno-
suppressive agents (administration of CSA or MTX after
DLI for 2-4 weeks) reduced the incidence of DLI-asso-
ciated acute GVHD without affecting relapse or survival
[41]. For patients with hematological relapse after receiv-
ing allo-HSCT, the donor GPBPC infusion treatment
group had a better outcome compared with chemother-
apy; this finding has been demonstrated in both patients
under HLA-matched and HLA-mismatched/haploidentical
T-cell-replete HSCT groups [42,43]. A later study demon-
strated that mDLI treatment also had a prophylactic effect
against relapse in high-risk leukemia patients after either
of these types of HSCT [44,45]. Recently, our team con-
cluded that risk stratification-directed interventions with
mDLI in MRD-positive patients with standard-risk acute
leukemia could prevent leukemia relapse and further
improve transplant outcomes [46]. Based on these find-
ings, a series of clinical and basic studies were initiated to
separate the GVL effect from GVHD with modified DLI in
patients with hematological malignancies. These studies
found that GPBPC harvests contained more CD34+ cells,
Th2-type cells and type II cytokines than non-primed per-
ipheral lymphocyte harvests, which contribute to the
lower incidence of aGVHD [32,47]. Meanwhile, the type I
cytokines, like IFN-g, was kept and capable of promoting
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with leukemia cells [48]. However, the effects of short-
course immunosuppressive agents on these lymphocytes
remain to be evaluated.
Prophylaxis and Management of GVHD
GVHD is the main complication post-HSCT, and Chinese
doctors must address this condition due to the high pro-
portion of haplo-HSCT cases. Thus, several novel strate-
gies to prevent GVHD have been devised.
The application of low-dose MTX has been demon-
strated as a novel regimen for the treatment of GVHD by
Peking University research group in different studies. Data
from a recent report suggested that MTX in combination
with low-dose methylpredinisone was well-tolerated and
effective when used as the first-line treatment for aGVHD
[49]. It has also been suggested that MTX is a well-toler-
ated, effective, and inexpensive agent when used as a first-
line treatment in combination with other immunosuppres-
sive agents for cGVHD, especially for skin or single organ
involvement without concomitant thrombocytopenia [50].
This finding is also supported by a consensus on clinical
practices in cGVHD [51].
Lai et al. recently described the efficacy of a new GVHD
prophylaxis regimen that combines CSA and MTX with a
short 30-day course of low-dose (500 mg/d) mycopheno-
late mofetil. After allo-HSCT with identical sibling donors,
the incidence of acute GVHD was 16% (9.5% for grades
2-4 GVHD and 1% for grades 3 and 4 GVHD). The cumu-
lative incidence of chronic GVHD was 53%, and 28% of
these patients experienced the extensive type of disease
[52]. Xia et al. reported that basiliximab has a similar effect
on aGVHD but superior activity against cGVHD com-
pared with daclizumab [53].
Nevertheless, most of the studies mentioned above are
retrospective, and thus, further prospective and multi-cen-
ter, randomized, controlled studies are needed.
In addition to drugs and antibodies, immunomodulatory
cell transfusion may be a more specific method to protect
patients from GVHD. Chen et al. reported that heteroge-
netic bone marrow mesenchymal stem cells (MSCs) could
suppress T cell activation. MSC pretreatment was useful
in the prevention of GVHD in HLA-mismatched bone
marrow transplantation [54]. Xiang et al. reported transfu-
sion of MSCs expanded from the BM of volunteers in
vitro was a safe and effective salvage therapy for patients
with steroid-resistant cGVHD, which might be mediate by
increasing ratio of CD5 + CD19+/CD5-CD19+ regulatory
B cells and CD8 + CD28-/CD8 + CD28+ T cells [55].
However, the cotransplantation of MSCs and HSCs may
prevent GVHD while elevating the risk of relapse and
therefore must be handled with extreme caution.
Basic and Pre-clinical researches on GVHD have also
been highly regarded in China. Zhao showed blockade of
osteopontin(OPN) could reduce alloreactive CD8+
T cell-mediated GVHD in animal model: OPN promoted
the migration and infiltration of naive and alloreactive
CD8(+) T cells into host organs; it also facilitated activa-
tion and viability of donor-derived CD8(+) T cells via
synergizing with CD3 signaling. This findings could vali-
date OPN as a potential target in GVHD prevention [56].
As mentioned above, MMF is an important regimen in
controlling GVHD, yet the therapeutic effect of MMF
varies in patients. Huang et al. firstly reported the pre-
sence of the IMPDH1 IVS8-106 G/G genotype of Inosine
monophosphate dehydrogenase (IMPDH, target enzyme
of MMF) in recipients was associated with a significantly
higher incidence of aGVHD than other genotypes, in
both unrelated and sibling transplantation cohorts [57].
This finding would contribute to the individualized ther-
apy of GVHD according to gene polymorphism.
There are also many promising pre-clinical studies
focused on the potential application of immune cells in
controlling GVHD, such as umbilical cord blood (CB)
derived stromal cells [58], ex vivo expanded CB CD4 +
CD25+ Foxp 3+ regulatory T cells [59], as well as CXCR4-
transduced MSCs, which maintained their immunosup-
pressive capacity and showed enhanced migration capacity
in vitro, thus controlled the occurrence of GVHD more
effectively [60].
In short, the progression of these basic and pre-clini-
cal studies would hopefully ameliorate the clinic prac-
tices of controlling GVHD in near future.
Modified HSCT for elderly patients
The outcome of transplantation in patients older than
60 years of age remains unsatisfactory with a low complete
remission (CR) rate and poor overall survival (OS) due to
prolonged pancytopenia and an elevated chemotherapy-
related mortality, etc. [61]. Allogeneic stem cell transplan-
tation after nonmyeloablative or reduced intensity condi-
tioning shows some curative effects for acute leukemia in
elderly patients; however, the transplant comorbidities
associated with GVHD and infection remain obstacles for
this population [62].
Mouse models infused with high doses of G-CSF-mobi-
lized allogeneic spleen cells after cytarabine chemother-
apy without immunosuppressive pretreatment exhibited
rapid hematopoietic recovery and persistent microchi-
m e r i s mw i t h o u tG V H D .A ia n dc o l l e a g u e sd e s i g n e da
clinical control study to show the superiority of “mini-
HSCT” over chemotherapy for elderly patients suffering
from AML. This HSCT protocol mainly consisted of
induction chemotherapy plus the infusion of HLA-mis-
matched G-PBSCs. Patients who received this treatment
had a higher complete remission rate and disease-free
survival over 2 years with no observable GVHD. These
results indicate that G-PBSCs in combination with
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treatment method for AML in elderly patients. This find-
ing warrants further multi-center studies to confirm the
results and determine if the same method can be applied
in the treatment of ALL or other hematopoietic malig-
nancies [63]. Besides, mechanism of “mini-HSCT”
remains to be investigated.
Prospects for the HSCT in China
As mentioned above, multi-center prospective studies and
researches connecting “bench to bed” are essential to pro-
mote the development of HSCT in China. Actually, there
have been successful multi-center trials conducted in
general hematology and molecular diagnostics, such as the
prospective study “Molecular Diagnosis and Individualized
Treatment of Acute Leukemia” supported by the National
High Technology Research and Development Program
(Program 863). Nevertheless, many challenges remain in
the HSCT field: (1) Compared with many well developed
international registries, for example, the European Group
for Blood and Marrow Transplantation (EBMT), the Chi-
nese Hematopoietic Stem Cell Transplantation Associa-
tion must make considerable progress in establishing itself
as a leader in clinical trials in addition to its role in data
management [2]. (2) Standardization would contribute to
the improvement and modification of the entire system by
allowing results from multiple centers to be compared.
However, standardized practices are associated with more
precise diagnoses, risk stratification, and corresponding
individualized treatment rather than solitary therapies that
vary from center to center. The dissemination of techni-
ques is more difficult from experienced centers to smaller
HSCT units due to the complexity of the HSCT system,
which requires more experienced doctors and diagnostic
technologies. (3) Benefit-sharing mechanisms are essential
to the success of multi-center clinical trials. A well-devel-
oped system would allow all participating units to access
data and analyze results from different angles. On the
other hand, some experienced centers or institutes have
the responsibility to lead clinical research programs apply-
ing for financial support, such as the key programs 973
and 863 of China, and to develop well-organized trials.
Next, two strategies can be employed to promote the
connection between basic research and clinical practice in
the field of Chinese HSCT. Firstly, Chinese researchers
must make significant progress in identifying the underly-
ing mechanisms of well-developed clinical models, such as
haplo-HSCT. This unique diagnosis and treatment system
in turn provides a perfect opportunity to analyze and com-
pare the differences among clinical and animal models.
Secondly, translational researchers must pursue promising
cellular or animal experiments. For example, researchers
from Jilin University, China, found that IFN-g promotes
graft-versus-leukemia effects without directly interacting
with leukemia cells in mice after HSCT [48]. Therefore, it
would be very interesting to investigate the potential
enhancement of GVL effects in DLI or reduced intensity
HSCT in patients by manipulation of IFN-g.
In summary, it would be very meaningful for Chinese
scholars to participate in translational researches of clin-
ical significance, such as immune tolerance in HLA-mis-
matched HSCT, the distinction between GVHD and
GVL, and the association between infection and chronic
immunologic imbalance.
Conclusion
China has made substantial progress in the field of allo-
HSCT during the past three decades, particularly in the
clinical applications and mechanism researches of
haplo-HSCT system, strategies to overcome relapse and
GVHD, and modified HSCT for elderly patients. With
the development of multi-center clinical trials and
advances in translational research, these unique fields of
allo-HSCT in China will have a promising future and
contribute more to the world HSCT system.
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